A comparative cost-benefit analysis of electronic brachytherapy vs. high-dose-rate iridium-192 for exclusive vaginal cuff treatment in post-operative endometrial cancer
While <sup>192</sup>Ir HDR remains the standard in brachytherapy due to its versatility, eBT presents a cost-benefit alternative for exclusive vaginal cuff treatments, particularly in settings where infrastructure limitations restrict isotope-based brachytherapy. These findings support the complementary role of eBT in clinical practice, optimizing resource allocation without compromising dosimetric quality.
Authors
- S. Pellejero (ORCID: https://orcid.org/0000-0003-2070-4542)
- S. Lozares (ORCID: https://orcid.org/0000-0002-1530-5662)
- Víctor González‐Pérez (ORCID: https://orcid.org/0000-0002-9289-6742)
- Marta Sánchez-Casi
- P. Castro Peña
- Tomás González-González
- Mireia Pallarés-Ripollés
- Antonio Herreros-Martínez
Institutions
- Universidad de Zaragoza (ES)
- Fundación Instituto Valenciano de Oncología (ES)
- Hospital Universitario Miguel Servet (ES)
- Hospital Clínic de Barcelona (ES)
- Universidad de Navarra (ES)
Publication Details
- Journal
- Journal of Contemporary Brachytherapy
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5114/jcb.2025.152539
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00